Dr. Roobik Azarnia has over 25 years of experience and expertise in the in-vitro diagnostics industry (IVD.) For over 10 years, he directed biosensor and immunomagnetic-based R&D at Coulter Corporation of Florida and Immunicon Corporation of Pennsylvania. Prior to that he was co-founder and president of MegaTechnologies, Inc., a start-up biotech company engaged in home glucose monitoring device development.
Before joining the IVD industry, Dr. Azarnia held a faculty position as Associate Professor of Physiology and Biophysics at the University of Miami School of Medicine.
Dr. Robert Ray is a biochemist with over 30 years of experience in the in-vitro diagnostics industry. Dr. Ray was Co-Founder, President and CEO of FlexSite Diagnostics, a leading diagnostics company targeting home diabetes testing solutions for HA1c and kidney screening, which was later sold to Geonositcs in 2010. Prior to FlexSite, he was President of CheckPoint Development, Inc., a consulting and contracts development enterprise. He has also served as Vice President of Home Diagnostics Inc., Business Manager of Coulter’s Chemistry business, President of London Diagnostics, Vice President of R&D for Baxter Dade, and General Manager for Immunosystems at Beckman Instruments.
Dr. Ray holds a Bachelors degree in Chemistry, a Masters degree in Biochemistry, and a Doctorate in Biochemistry, all from The University of Nebraska. He is also a graduate of The University of California, Los Angeles Graduate School of Management.
Mr. Vincent Cheung has over 15 years of medical device industry experience with various multinational companies such as Edwards Lifesciences, Johnson & Johnson, and B.Braun. He was actively involved in cardiovascular product development, setting up Class II/III manufacturing operations, quality system management, regulatory affairs and compliance activities. In 2005, Mr. Cheung was relocated from the United States to Singapore to establish heart valve manufacturing presence in Asia for Edwards Lifesciences where he was instrumental in attaining successful USFDA and Japan PMDA quality system inspection, ISO 13485 Quality Management System certification, and CE Mark audit.
Vincent holds a Bachelors degree in Medical Microbiology from the California State University at Long Beach, is an Executive Committee member of the Biomedical Engineering Society of Singapore, and consultative member for the Bioengineering Department at the National University of Singapore.
Mr. Pierre Hennes has significant international experience in technology and new venture creation and is responsible for Sentec's strategic business development initiatives. He is the Managing Partner of Extream Ventures, a Singapore-based early-stage VC firm launched in 2009, funded in part by the Singapore Government's National Research Foundation. He is also a Partner of Upstream Ventures, a Singapore-based seed & startup investment firm launched in 2003. Pierre has backed successful technology companies such as Singular ID (Bilcare), Property Guru (IS24/Deutsche Telekom), JustCommodity Software Solutions and Tagit, and serves on the board of several portfolio companies.
Until recently, Pierre served as the Chairman of the Business Angels Network of Southeast Asia (BANSEA), Singapore's largest network of angel investors. Pierre earned a B.A. with Honors in International Relations from Boston University, and an MBA from New York University's Stern School of Business.
Mr. Colin Tan has over 6 years of experience in project engineering and project management at the following: Quattro Vascular, Singapore; Circle Medical Devices, Los Gatos, CA; ALZA Corporation, Johnson & Johnson, Mountain View, CA. His expertise is in managing medical device projects through the major phases of product development. He has extensive experience in leading projects from conceptualization and prototyping, through design verification and validation, to clinical trials, manufacturing and product launch. Projects included glucose monitors, insulin delivery systems, ocular shunt implants, mitral valves, balloon catheters, vascular access ports, gastro-intestinal implants and endoscopy and laparoscopy devices.
Colin holds a BS in Biomedical Engineering from Northwestern University, and an MS in Bioengineering from Stanford University.
Established in Singapore in 2011, Sentec is dedicated to the discovery, development, and commercialization of technologies that enable diabetics to test and manage blood glucose levels more conveniently and effectively than current solutions.
Our company is located in Singapore, a dynamic city with an advanced healthcare ecosystem, strategically located in the heart of the world’s largest growing market for diabetes care. We are backed by a strong, committed team of individuals and partners with complementary experience in engineering, design, product development, manufacturing, QA/QC, regulatory affairs, finance and operations.